NHS Federated Data Platform: Palantir
Tuesday, 17 November 2026
Contributions
Motion made, and Question proposed, That this House do now adjourn. —( Rachel Hopkins .)
Martin Wrigley (Newton Abbot) (LD)Liberal Democrat
I start with a declaration of my interests, as I chair the all-party parliamentary group for UK innovation startups and SMEs. I thank the Minister for his statement yesterday, which answered so many of the asks I made in my April debate in Westminster Hall, but this is still an important issue that we have to discuss. It is not simply a question about one NHS contract, but a test of whether the Government are serious about cleaning up politics, fixing public procurement and building UK sovereign capability. The Government have spoken repeatedly about using procurement to support British innovation, British businesses and national capability, and this is an opportunity to demonstrate that those commitments mean something in practice. I previously received public assurances that the NHS medium-term planning framework would not be used to force the continued roll-out of Palantir’s federated data platform across the NHS. At yesterday’s statement, I welcomed the investment being directed towards interoperability, common standards and future NHS digital capability, rather than simply extending the life of what increasingly appears to be Palantir’s lame duck FDP. When I first started examining this issue, I genuinely was not sure whether the FDP had become so embedded that it could no longer be switched off. My conclusion now is that it can be switched off. In fact, I suspect that outside a relatively small number of trusts, with Chelsea and Westminster perhaps being an example, most clinicians and patients would barely notice. If that assessment is wrong, it should be independently proven, and I would like the Minister to commit to commissioning an independent audit of the FDP’s actual usage, its genuine operational dependency and the transaction options available. Crucially, that audit must be conducted independently of NHS England, which has been closely associated with the programme and its delivery. The FDP has been deeply problematic from the start. The original political pitch was essentially for software as a service, with flashy dashboards sold to Boris Johnson for just £1. We saw a political climate in which the likes of Peter Thiel, Donald Trump and Dominic Cummings were all part of a wider ecosystem promoting this approach to Government technology. Software as a service does not work for this kind of contract. It is not how we build sovereign capabilities. We are paying Palantir to develop intellectual property and know-how, which it then owns and can sell to others, while the NHS just gets the use of it.
The Parliamentary Under-Secretary of State for Health and Social Care (Mr James Frith)Labour
indicated dissent .
Martin WrigleyLiberal Democrat
I see the Minister shake his head, but it is in the contract. Palantir owns intellectual property rights that are not brought in by the NHS. In fact, this is the worst contract I have ever seen in my commercial life. It is a monument to the previous Government’s financial incompetence. UK procurement needs to move away from software as a service and start building its sovereign capabilities.
Andrew George (St Ives) (LD)Liberal Democrat
I congratulate my hon. Friend not only on securing this debate, but on the manner in which he has conducted himself in investigating these matters. He will know that we have been investigating them on the Health and Social Care Committee, too. In relation to all the weaknesses, and in particular in relation to the procurement that he describes, does he not agree that the Government should be maximising the opportunity of the break clause next year, so that this matter can be properly investigated as soon as possible?
Martin WrigleyLiberal Democrat
My first point is that we could switch the system off tomorrow, and it would not impact the NHS. In fact, the NHS should not be dependent upon a single supplier for its future data architecture.
Tom Gordon (Harrogate and Knaresborough) (LD)Liberal Democrat
My hon. Friend has been a doughty campaigner on this issue and has gone about it in an exemplary way. He has already mentioned that data sovereignty will be key looking forward, but does he agree that we should ensure that no such contracts are handed out in future across all Departments?
Martin WrigleyLiberal Democrat
I agree entirely with my hon. Friend. In fact, I will go one stage further and say that trust is as important as data sovereignty, and right now we do not have a system that people trust. Recent events only reinforce concerns. Yesterday, Tom Watson circulated a letter that appears to many observers to be another example of highly aggressive lobbying. I would appreciate clarification regarding communications and briefings between Palantir and the Government immediately before and after yesterday’s statement. Recent public commentary from Lord Watson has given the impression that the continuation of the contract is somehow guaranteed, but that decision has not yet been made. The Government must be seen to act independently, and the revolving door between the Government and Palantir must be challenged.
Rachael Maskell (York Central) (Lab/Co-op)Labour (Co-op)
I really appreciate the hon. Member’s work in this area. I, too, have been following this contract very closely since my time on the Health Committee and the awarding of the contract. Does he share my concern that the two-year extension enables Palantir to embed itself further into those systems, and thus place itself in a privileged position to win contracts from 2029, perhaps as Palantir UK?
Martin WrigleyLiberal Democrat
I agree entirely, and that power of incumbency is what I am about to speak about. The public need to be confident that procurement decisions are being made on the basis of value, capability and public interest, not relationships or incumbency. Following yesterday’s statement, will the Minister serve the contractual termination assistance notice, and if so, when? And—an equally important question—how will the Government ensure that Palantir’s incumbency advantage does not distort future competition?
Dame Chi Onwurah (Newcastle upon Tyne Central and West) (Lab)Labour
I congratulate the hon. Member on initiating the debate. He exhibits the same tenacity, expertise and determination in pursuing this issue as he does on the Committee of which we are both proud to be members. He has raised the issue of incumbency. As he has said, Palantir turned a £1 contract during covid into a £350 million contract now. Now it will have two years in which to exercise that incumbency. Does he think it is possible to create a level playing field for the next tender, given that Palantir will have access to all the data, all the systems, all the architecture and those who are designing the tender?
Martin WrigleyLiberal Democrat
I greatly enjoy serving on the Select Committee with the hon. Lady, and I fully agree with her. That is the challenge that we need to set the Minister: to prove that this can be done. There is another issue that should not be ignored: how Palantir continuously undermines people’s trust. Its leadership has repeatedly made political and ideological statements, which would attract substantial scrutiny if they came from a major British supplier or a company on the Cabinet Office strategic suppliers list, which, curiously, they have not. Why are we willing to apply a different standard simply because Palantir is some weird foreign company?
Iqbal Mohamed (Dewsbury and Batley) (Ind)Independent
I thank the hon. Member for securing the debate, and for his tireless work on this topic. Does he agree that British procurement rules should be founded on human rights and ethics, and that ethical procurement should be the foundation of any public sector procurement that we make? Palantir has been used in violations of international human rights in Palestine—in Gaza—and it has been used to enforce illegal searches and violence by ICE in the United States. Statements made by its executives clearly demonstrate that it is a company that cannot be trusted, and that it lacks ethics and morality. Is that not one more reason for us to sever all ties with it?
Martin WrigleyLiberal Democrat
I do agree, but I think that Palantir actually causes a bigger problem, which is that it is not actually very good at what it claims to be able to do. That is the reason why we should not be renewing its contract, but we should be pursuing ethical procurement as well.
Iqbal MohamedIndependent
Data is the new oil, and the NHS data on patients and research is so valuable. Is there a risk that Palantir, through this contract, will have unauthorised access or will siphon off data without permission?
Martin WrigleyLiberal Democrat
We have seen that Palantir has been authorised to access such data, which was previously unknown and undeclared. My point is not that Palantir’s political opinions should determine procurement outcomes, but that scrutiny should be applied consistently. To replace the current approach, I believe that we need an independent NHS design authority to control the architecture of the future FDP, rather than it being controlled by the supplier; multiple suppliers, rather than a single controlling company; and open, common standards—which the Minister talked about in his statement on Monday, and which I fully support—that should be interoperable by design, so that we can take out pieces and plug in another company to replace them.
Olly Glover (Didcot and Wantage) (LD)Liberal Democrat
My hon. Friend is suggesting a very helpful and well-thought-through solution to some of these problems, and what he is suggesting is very important for public trust in future. Does he agree that we have enough problems with totally wild conspiracy theories out there, let alone things like Palantir, which looks like a genuine conspiracy, so what he is recommending and asking the Minister to comment on are all the more important?
Martin WrigleyLiberal Democrat
I did laugh at Palantir’s comments. In fact, its manifesto was referred to as “the ramblings of a comic book villain”.
Anna Dixon (Shipley) (Lab)Labour
I thank the hon. Gentleman for securing this debate, and for inviting experts from the NHS’s analytical and data community into Parliament to meet us last week. Does he agree that there is already sufficient capability and innovation in the NHS to build the data systems, and that the need for Palantir’s federated data platform is largely redundant because of that expertise? It would be better to put those resources into supporting innovation in the NHS, with some of our great small and medium-sized enterprises working as partners.
Martin WrigleyLiberal Democrat
Yes, it was shown very clearly by the people who are delivering for the NHS right now that Palantir is not capable of delivering the sorts of results that we can already get from bodies such as Manchester’s integrated care board, which is delivering innovation in advance and more quickly than Palantir can. The final thing we need in my list, after interoperability by design, is a competitive process that allows British SMEs and start-ups to participate without the usual level of bureaucracy. The future should be an ecosystem, not a monopoly. Unfortunately, it comes back to procurement reform. The Government have spoken about a new procurement strategy, about using public procurement to support British innovation and business, and about building domestic capability, rather than reinforcing dependency and vulnerability. The Palantir contract is a real-world test of those principles. It is a test for the Government to see if they will truly implement “using public procurement to back British business”, as stated in the Budget. Finally, there is substantial expertise across this House. There are Members with wide experience in health, digital transformation, technology, procurement and business growth. I therefore invite the Minister to engage regularly with interested Members as this process develops—not to influence contract awards, because that would be entirely inappropriate, but to ensure that the principles underpinning the procurement process are transparent, competitive, fair and firmly aligned with the public interest. This is about more than Palantir messing up our NHS; it is about whether the Government want to build our sovereign capabilities, or whether we will continue down a path of dependence on a single, failing foreign provider.
The Parliamentary Under-Secretary of State for Health and Social Care (Mr James Frith)Labour
I thank the hon. Member for Newton Abbot (Martin Wrigley) for raising this important issue. It has been a pleasure exchanging with him, in corridors and more formal settings, on areas where we definitely agree as well as others where we are yet to agree, which I will come on to. It is a pleasure to have the opportunity to build on my extensive statement and questions from Members yesterday, and to explain the Government’s approach to the NHS federated data platform. As I said yesterday, after a period of review, the Government are launching a new procurement to end the contract in March 2029. This will give us the opportunity to build the next generation of the FDP with new capability. While we prepare for the next generation of the FDP, the current supplier will remain in place. This will provide the necessary continuity of care, preserving the benefits to patients and the healthcare system that we have already achieved, while providing time to run a fair and rigorous procurement process, which it is important to get right.
Martin WrigleyLiberal Democrat
Is the Minister aware that the “Today” programme on the BBC this morning talked about a brief it had from Palantir saying that it had been awarded the contract as a continuation to show how good it was. Will he ensure that Palantir understands the message he is giving?
Mr FrithLabour
This contract—a seven-year contract—was awarded in 2023. This is year 3, and we have announced that the contract will end in March 2029. A letter from Palantir to me and Secretary of State confirms in its third paragraph: “The FDP programme team has done a tremendous job of ensuring that exit arrangements are clear, and that the NHS has all the rights and all the support it needs to transition to a new supplier when the contract ends. We will ramp up exit preparation over the next two years and work with the NHS to ensure that the public and the industry understand that there is no lock-in.” Through engagement with the market under the new procurement we have launched, we can bring forward innovative solutions that build on today’s capabilities and meet the needs of tomorrow in ambition and appetite as well as in capability. This decision is driven by the Government’s aim to secure for patients the technology that supports their care, while improving productivity to give the NHS and social care more choice, greater resilience and less dependence on any one single supplier.
Iqbal MohamedIndependent
I have two very quick questions. First, what are the obstacles in the way of exercising the break clause next year? Secondly, can the Minister assure all our constituents that no NHS data will have been given to or taken by Palantir if and when it leaves?
Mr FrithLabour
The data remains NHS, as does the intellectual property, and there is no lock-in. In the announcement yesterday, I confirmed to the House that we are beginning a new procurement process, and I will come on to confirm more details of that. I will now try to make a bit of progress. In making this decision, we deliver on two objectives: continuing the use of technology to transform the NHS and supporting the Government’s strategy to build UK AI technology capabilities. We want a more diverse and innovative supply market, including greater use of sovereign AI, as well as any internationally developed capabilities. The NHS FDP has the power to transform and is transforming how services co-ordinate care. It gives the NHS the tools to bring together information from disparate NHS systems, and manage and analyse it in one place. This is a system that trusts and integrated care boards need and are using. It is an important part of our objective to secure the best digital data and tech to deliver the health and care system we need. This requires us to draw on innovative solutions both locally and nationally. As I said yesterday, 137 trusts are already delivering benefits. In Greater Manchester, which the hon. Member for Newton Abbot references, hospital teams book cancer tests so that patients can choose to be tested sooner at another hospital. This requires us to draw on innovative solutions locally and nationally. In making better use of operating theatres, planning discharges, reducing list sizes and supporting vaccine supply, the benefits of the FDP are being relied on by our trusts. In North Tees and Hartlepool, the FDP tracks discharge actions so that nothing blocks a patient from getting home, and, importantly, frees up beds for admission. As I stated yesterday, alongside the new procurement, we will work with a range of providers to develop new capabilities and expertise, beginning with maternity care. This will bring together innovative providers to help to tackle fragmentation in data and digital systems, while exploring how NHS priorities can support the growth of UK AI capability. We do not want to sacrifice these gains; we want to encourage the full realisation of this capability so that more people receive the care they need. That means spending the time to deliver a fair procurement process that engages with the very stakeholders the hon. Gentleman encourages, as well as industry and the market, and supports opportunities for UK companies. This is not a quick process, but a methodical one that will ensure interoperability and the common standards announced yesterday in agreement with the work by the hon. Gentleman and colleagues from Select Committees. This relates to the second objective: how we change the procurement of future technology to benefit not just the NHS, but industry, delivering growth and employment opportunities. We want to do more to build UK AI and tech capability, and the new procurement of the NHS FDP will be a flagship for this. We want to invite, stir, spark interest and inspire innovative providers, UK and international alike, to tackle the data and digital fragmentation in this area of care and test how health priorities can create routes to build UK AI capability and resilience.
Dame Chi OnwurahLabour
I agree with the points the Minister is making. However, the issue is that the same points around interoperability and supporting UK procurement were also part of the original tender for the federated data platform, which led to it being awarded to Palantir and a consortium. Will he set out how this differs from the original tender that was followed some years ago? Secondly, in this case, Palantir will be the incumbent. How will the Minister ensure that other companies, small and large, have the same kind of access to the existing FDP architecture, knowledge, information and users as Palantir?
Mr FrithLabour
I thank my hon. Friend, the Chair of the Science, Innovation and Technology Committee, for her questions. I heard her concerns both in yesterday’s contribution and in the subsequent conversation that we had. This has my full attention, because incumbency cannot be allowed to be an advantage by design. I will ensure that the Procurement Act of 2023, which requires equal treatment, has my full attention in the drafting of the procurement. More details on that will follow, as I said in my statement yesterday. I refer Members to that statement for further information.
Rachael MaskellLabour (Co-op)
I am grateful for what the Minister is saying, but could he explain to the House how the two-year extension beyond the break clause aligns with what is coming from the Foreign Office with regards to our obligations under our sanctions regime and to the relationship of Palantir with the Israeli Government?
Mr FrithLabour
I thank my hon. Friend for her question. This is a decision to procure anew. It is not about other territories or one supplier and their executives holding a political view. It is a decision that is being taken to go to market for a new version—the next generation of FDP. That process began yesterday in earnest. It is not, as I have said, about where else Palantir supplies or who else it has as customers. It is about maintaining what the NHS makes possible—being able to check in sooner for cancer care, other hospital care or social care. We will build on the successes of the FDP to date. We will procure anew the next generation and ensure exit and transition for March 2029. Throughout this period, trusts and ICBs can and should make full use of the capabilities of the NHS FDP to improve their performance and productivity, including those yet to sign up to or realise the full potential of the FDP. In this time, we will create an environment in which new technologies and suppliers can contribute new solutions to protect the capabilities that the NHS relies on today. For those who need reassurance on the security of their data, I can say that security and data protection are a core principle of the FDP in the NHS. That will not change. As I said repeatedly yesterday, innovation adoption moves at the speed of trust. People should be reassured that the NHS FDP is a federated network of systems, each controlled by the relevant hospital or ICB. The use of the FDP and its different products is driven by the local NHS and the data is under their control, just as in the national instance it is controlled by NHS England. Data access is tightly governed. Access to data is for authorised users only and for approved purposes only, with access logged and audited. There is no overseas processing of any type of data by the NHS FDP programme. Data is held in UK data centres and does not leave the UK. I believe that this decision strikes the right balance between maintaining the needs of patients today while confirming that the contract will end in March 2029, when we will have a new-generation FDP in our NHS. That is a process that I am happy to report begins today. Question put and agreed to.
House adjourned.
Source: UK Parliament Hansard API. Debate ID: 5439285.